Full Text View
Tabular View
Study Results
Related Studies
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
This study has been completed.
Study NCT00288704   Information provided by Regeneron Pharmaceuticals

First Received on February 6, 2006.   Last Updated on December 1, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Familial Cold Urticaria
Muckle-Wells Syndrome (MWS)
Genetic Diseases, Inborn
Additional conditions recognized in this trial
Cellulitis
Cryopyrin-Associated Periodic Syndromes
Eosinophilia
Urticaria
More general conditions related to this trial
Connective Tissue Diseases
Hematologic Diseases
Hereditary Autoinflammatory Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Infection
Inflammation
Leukocyte Disorders
Pathologic Processes
Skin Diseases
Skin Diseases, Genetic
Skin Diseases, Infectious
Skin Diseases, Vascular
Suppuration
Interventions listed in this trial
rilonacept 160 mg
Placebo
Sponsors listed in this trial
Regeneron Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services